[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Ovarian Cancer Therapeutics Market to Witness Three-Fold Growth by 2020, According to GlobalData

26 Apr 2012 • by Natalie Aster

In 2011, the ovarian cancer therapeutics markets in key countries (the US, the UK, Germany, France, Italy, Spain, Japan, Brazil, Russia, India and China) were worth $736.7m collectively. The ovarian cancer therapeutics market is expected to witness three-fold growth by 2020, reaching $2,352m at a CAGR of 13.8%. This high growth rate is expected due to the strength of the pipeline candidates, which are anticipated to change the treatment paradigm of ovarian cancer when launched.

The ovarian cancer pipeline is strong, with 134 molecules in different stages of clinical development. The majority of these are first-in-class molecules, which have distinct advantages over the currently marketed products, and are expected to bring a change in the disease course and clinical outcomes. A number of pipeline molecules have entered Phase III trials for ovarian cancer. There are 12 molecules in late stage development (pre-registration and Phase III). Some of these Phase III molecules will have an impact in the ovarian cancer market when launched.

According to the report “Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020” by GlobalData, the growth in the market will be attributed to the continuous shift from the use of chemotherapy regimens to regimens containing high-price targeted and biological agents.

Report Details:

Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
Published: February, 2012
Pages: 438
Price: US$ 6.995,00

The ovarian cancer market has high unmet need in terms of both efficacy and safety, with a cure for the disease being the most important unmet need in the market. Ovarian cancer treatment currently consists mainly of surgery and chemotherapy – however, under these regimens many patients suffer a relapse, or develop recurrent tumors that are resistant or refractory to further therapy. The inability of current market offerings to alter the natural course of the disease and improve patients’ quality of life indicates that there is an unmet need for drugs with better efficacy profiles.

More information can be found in the report “Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020” by GlobalData.

To order the report or ask for sample pages contact [email protected]


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest